Health Ministry proposes GSDP rules, eases Schedule M norms for 3 drug categories
Synopsis
Key Takeaways
The Union Ministry of Health and Family Welfare on Thursday, 19 November 2026, proposed amendments to the Drugs Rules, 1945, introducing a formal Good Storage and Distribution Practices (GSDP) framework and easing certain revised Schedule M requirements for three specific drug product categories. The dual-track reform is aimed at both tightening quality controls across India's pharmaceutical supply chain and addressing practical manufacturing concerns raised by industry stakeholders.
What the GSDP Framework Proposes
The proposed GSDP guidelines, developed on the basis of recommendations by the Central Drugs Standard Control Organisation (CDSCO), are designed to ensure that the quality, safety, efficacy, and integrity of pharmaceutical products are preserved at every link in the distribution chain — from manufacturers and importers to end patients. The draft notification covers procurement, purchasing, storage, transportation, documentation, and record-keeping, bringing Indian norms closer to international regulatory standards.
Notably, the GSDP framework would apply uniformly across all actors in the pharmaceutical distribution ecosystem, a significant structural step given the fragmented nature of drug logistics in India. The ministry issued the draft through Gazette Notification G.S.R. 985 (E), dated 6 November, published in the Gazette of India, inviting public comment ahead of finalisation.
Schedule M Relaxations for Three Product Categories
In a separate but simultaneous draft notification issued on 6 November, the ministry proposed regulatory flexibility under the revised Schedule M for medicinal gases, empty gelatin capsules, and disinfectant fluids. The move follows representations from industry stakeholders who flagged that certain manufacturing requirements under the revised Schedule M were not applicable — or were technically incompatible — with the production processes of these categories.
The Drugs Technical Advisory Board (DTAB) examined the matter at its 93rd meeting held on 16 February 2026 and observed that some Schedule M provisions were not relevant to the manufacturing processes of these specific product segments, lending technical backing to the proposed carve-out.
Why This Matters for India's Pharma Sector
India is the world's largest supplier of generic medicines by volume, supplying roughly 20% of global generic drug exports. Any regulatory tightening or recalibration of domestic manufacturing and distribution norms carries direct implications for both domestic patients and export markets. Critics and patient advocacy groups have long argued that distribution-chain lapses — including improper storage and cold-chain failures — contribute to substandard drug quality reaching end consumers.
This comes amid heightened regulatory scrutiny of Indian pharmaceutical manufacturers following a series of international quality alerts in recent years. The GSDP proposal, if notified, would create a legally enforceable quality standard for the distribution segment, which has historically operated under softer guidelines.
What Happens Next
Both draft notifications are open for stakeholder feedback before being finalised. Industry bodies, drug manufacturers, and distributors are expected to submit representations, particularly on the GSDP compliance timelines and the precise scope of the Schedule M exemptions. Once the feedback period closes, the ministry is expected to issue the final Gazette notifications incorporating any revisions.